Arbutus Biopharma (ABUS) reported Q1 earnings Wednesday of $0.87 per diluted share, swinging from a loss of $0.13 a year earlier.
Two analysts surveyed by FactSet expected a loss of $0.03.
Revenue for the quarter ended March 31 was $179.1 million, compared with $1.8 million a year earlier.
Two analysts surveyed by FactSet expected $800,000.
Shares of Arbutus Biopharma were up 3.3% pre-bell.